Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation

British Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 121-124

  Marier, Jean Francois ^a   Lor, Mary ^a   Morin, Josée ^a   Roux, Lionel ^a   Di Marco, Marika ^a   Morelli, Gaetano ^a   Sædder, Eva Aggerholm ^b  

^a MDS Inc   (Canada)

^b Nycomed Denmark   (Denmark)

Author keywords

Fentanyl; Matrix transdermal delivery system; Performance; Pharmacokinetics; Safety

Indexed keywords

FENTANYL; NALTREXONE;

ADHESION; ADULT; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NAUSEA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADULT; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; FENTANYL; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 33845412248     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02758.x     Document Type: Article

References (10)

1. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-38.
2. Fiset P, Cohane C, Browne S, Brand SC, Shafer SL. Biopharmaceutics of a new transdermal fentanyl device. Anesthesiology 1995; 83: 459-69.
3. US Food and Drug Administration. Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements, 2004 and 2005. Available at: http://www.fda.gov/medwatch/safety.htm (last accessed: 8 August 2006).
4. Freynhagen R, von Giesen HJ, Busche P, Sabatowski R, Konrad C, Grond S. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005; 30: 289-97.
5. Woodroffe MA, Hays H. Fentanyl transdermal system. Pain management at home. Can Fam Physician 1997; 43: 268-72.
6. Tan HS, Pfister WR. Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm Sci Technol Today 1999; 2: 60-9.
7. U.S. Department of Health and Human Services. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. Washinton DC: Food and Drug Administration, Center for Drug Administration and Research 1999.
8. Marier JF, Lor M, Potvin D, DiMarco M, Morelli G, Sædder EA. Pharmacokinetics, tolerability and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharm 2006; 46: 642-53.
9. Lambropoulos J, Spanos GA, Lazaridis NV, Ingallinera TS, Rodriguez VK. Development and validation of an HPLC assay for fentanyl and related substances in fentanyl citrate injection, USP. J Pharm Biomed Anal 1999; 20: 705-16.
10. Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 1995; 29: 969-71.